Scalper1 News
Biotech Kite Pharma (KITE) acknowledged Monday that a patient in one of its clinical trials died, but said the death was unrelated to its drug candidate. Kite’s stock was pounded last week, falling 9% on Thursday and 3.5% on Friday, by a rumor of a patient death in the phase one trial of its candidate KTE-C19 in diffuse large B-cell lymphoma. On Monday, the company issued a formal update on the trial. “There was one patient death early in the Scalper1 News
Scalper1 News